| dc.contributor.author | Parperis, Konstantinos | en |
| dc.creator | Parperis, Konstantinos | en |
| dc.date.accessioned | 2021-02-23T14:38:27Z | |
| dc.date.available | 2021-02-23T14:38:27Z | |
| dc.date.issued | 2019 | |
| dc.identifier.issn | 0003-4967 | |
| dc.identifier.issn | 1468-2060 | |
| dc.identifier.uri | http://gnosis.library.ucy.ac.cy/handle/7/64116 | |
| dc.description.abstract | We read with great interest the article by Roddy et al 1, published in the Annals of Rheumatic Disease, an open-label study that examined 399 patients presented at primary care centres with exacerbation of gout. The patients were allocated to two treatment arms, one group received naproxen and the second group treated with colchicine, and the primary outcome measured changes in the pain level from baseline over the first 7 days after presentation. Diarrhoea and headaches were more commonly reported in the colchicine group … | en |
| dc.language.iso | en | en |
| dc.source | Annals of the Rheumatic Diseases | en |
| dc.source.uri | https://ard.bmj.com/content/early/2019/11/27/annrheumdis-2019-216643 | |
| dc.source.uri | http://www.ncbi.nlm.nih.gov/pubmed/31776116 | |
| dc.title | Open-label randomised pragmatic trial (CONTACT) comparing naproxen and low-dose colchicine for the treatment of gout flares in primary care | en |
| dc.type | info:eu-repo/semantics/article | |
| dc.identifier.doi | 10.1136/annrheumdis-2019-216643 | |
| dc.author.faculty | Ιατρική Σχολή / Medical School | |
| dc.author.department | Ιατρική Σχολή / Medical School | |
| dc.type.uhtype | Article | en |
| dc.contributor.orcid | Parperis, Konstantinos [0000-0001-6009-0130] | |
| dc.gnosis.orcid | 0000-0001-6009-0130 | |
